They indicate that DPP-4 inhibitor therapy during pregnancy could inhibit fetal programming toward obesity in the offspring of obese mothers, but more detailed research is required to confirm this observation [48]. The gene discussed is DPP4; the disease is obesity due to melanocortin 4 receptor deficiency.